Guías Clínicas 145 GUÍA CLÍNICA DE MANEJO Y TRATAMIENTO DE LA INFECCIÓN POR VIRUS DE LA HEPATITIS B - Ministerio de Salud, Chile childhood. An Australia antigen disease. Arch Dis Child 1973; 48: 794-9. 109.- Tabor E. Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol 1987; 21: 207-16. 110.- Janssen HL, van Zonneveld M, van Nunen AB, Niesters HG, Schalm SG, de Man RA. Polyarteritis nodosa with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gas-troenterol Hepatol 2004; 16: 801-7. 111.- Goedert JJ. Second Multicenter Haemo-philia Cohort Study. Prevalence of con-ditions associated with immunodeficien-cy and hepatitis virus infections among persons with haemophilia. Haemophilia 2005; 11: 516-28. 112.- Makris M, Baglin T, Dusheiko G, Giangrande PL, Lee CA, Ludlam CA, et al; Transfusion Transmitted Infection Working Party of the UK Haemophilia Centre Directors Organization. Guideli-nes on the diagnosis, management and prevention of hepatitis in haemophilia. Haemophilia 2001; 7: 339-45. 113.- Centers for Disease Control and Preven-tion (CDC). Blood safety monitoring among persons with bleeding disorders- United States, May 1998-June 2002. MMWR Morb Mortal Wkly Rep 2003; 51: 1152-4. 114.- Zúñiga P, Cifuentes L, Donoso M, Morales M. Guía clínica para el manejo de la hemofilia del niño y adulto. Garan-tías explícitas Ministerio de Salud 2006. 115.- Saab S, Cho D, Quon D, Ibrahim A, Dong P. Logan L. Same day outpatient transjugular liver biopsies in haemophi-lia. Haemophilia 2004; 10: 727-31. 116.- Stieltjes N, et al. Interest of transjugular liver biopsy in adult patient with hae-mophilia or other congenital bleeding disorders infected with hepatitis C virus. Br J Haematol 2004; 125: 769-76. 117.- Eastwood JB, Curtis JR, Wing AJ, de Wardener HE. Hepatitis in a maintenan-ce hemodialysis unit. Ann Intern Med 1968; 69: 59-66. 118.- Jones PO, Goldsmith HJ, Wright FK, Roberts C, Watson DC. Viral hepatitis: A staff hazard in dialysis units. Lancet 1967; 1: 835-840. 119.- London WT, Di Figlia M, Sutnick A, Blumberg BS. An epidemic of hepatitis in a chronic-hemodialysis unit. Australia antigen and differences in host response. N Engl J Med 1969; 281: 571-8. 120.- Rosenheim report: Hepatitis and the treatment of chronic renal failure. Report of the Advisory Group. London: DHSS; 1972. 121.- Control measures for hepatitis B in dialysis centers. In: Viral hepatitis inves-tigation and control series CDC hepatitis surveillance. Atlanta: CDC; 1977: 12-20. 122.- Tang S, Lai KN. Chronic viral hepatitis in hemodialysis patients. Hemodial Int 2005; 9: 169-79. 123.- Winearls CG, Recombinant human erythropoietin: 10 years of clinical expe-rience. Nephrol Dial Transplant 1998; 13 (Suppl 2): 3-8. 124.- Alter M J, Favero MS, Moyer LA, Bland LA. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis 1986; 153: 1149-51. 125.- CDC Update. Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other blood-borne pathogens in healthcare settings. MMWR 1988; 37: 377-82. 126.- Fabrizi F, Poordad FF, Martin P. Hepati-tis C infection and the patient with end-stage renal disease. Hepatology 2002; 36:3-10. 127.- Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin N Am 2004; 33: 655-70. 128.- Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-9. 129.- Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C vi-rus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-902. 130.- Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, et al. Impact of hepatitis B and C virus on kidney trans-plantation outcome. Hepatology 1999; 29: 257-63. 131.- Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of dialysis-associated diseases in the Uni-ted States, 1989 ASAIO. Trans 1991; 37: 97-109. 132.- Alter MJ, Ahtone J, Maynard JE. Hepa-titis B virus transmission associated with a multiple-dose vial in a hemodialysis unit. Ann Intern Med. 1983; 99: 330-3. 133.- Poblete H. XXV Cuenta de Hemodiálisis Crónica. Sociedad Chilena de Nefrolo-gía. ASODI 2005: 1-62. 134.- Lee BW, Yap HK, Tan M, Guan R, Quak SH, Choong L, et al. Cell-media-ted immunity in patients on hemodialy-sis: relationship with hepatitis B carrier status. Am J Nephrol 1991; 11: 98-101. 135.- Marcelli D, Stanhard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustement for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50: 1013-18. 136.- Gan SI, Devlin SM, Scott-Douglas VW, Burak KW. Lamivudine for the treatment of membranous glomerulo-pathy secondary to chronic hepatitis B infection. Can J Gastroenterol 2005; 19: 625-9. 137.- Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, et al. Hypoami-notransferasemia in patients undergoing long-term hemodialysis: Clinical and biochemical appraisal. Gastroenterology 1995; 109: 1295-300. 138.- Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, et al for Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408. 139.- Fabrizi F, Dulai G, Dixit V, Bunnapra-dist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Trans-plantation 2004; 77: 859-64. 140.- Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract 2006; 103: 89-93. 141.- Pérez J, Noriega LM, Vásquez P, et al. Seroprevalencia de Hepatitis B y C en pacientes VIH (+). Libro del XV Congreso Chileno de Infectología, 1998. 142.- Pérez C, Fuentes G, Cerón I, et al. Co-infección por VHB, VHC, en pacientes Gastroenterol. latinoam 2010; Vol 21, Nº 2: 89-147
n1-2010
To see the actual publication please follow the link above